Early palliative care for patients with multiple myeloma and aggressive lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the feasibility and preliminary efficacy of an early palliative care intervention for patients diagnosed with multiple myeloma and aggressive B cell lymphoma. Participants will be randomly assigned to receive either standard symptom screening or early palliative care alongside their usual cancer treatment. The study will measure various outcomes, including quality of life, symptom burden, and patient satisfaction, through questionnaires at multiple time points. Additionally, select participants will engage in semi-structured interviews to share their experiences with the intervention.

Why it matters

Who can join: the full rules

Patient eligibility criteria:

Inclusion criteria:

(i) Age ≥18 years; (ii) A new diagnosis of multiple myeloma or at progression of disease necessitating a change in treatment plan, or relapsed/refractory aggressive B cell lymphoma after one prior line of therapy; (iii) Eastern Cooperative Oncology Group (ECOG) performance status 0-3; (iv) Willingness to complete symptom screening; and (v) At least one ESAS-r-plus symptom scored at ≥3 at time of recruitment.

Exclusion criteria:

(i) Insufficient English literacy to complete study procedures; (ii) Hematologist-determined poor cognitive status; (iii) Current palliative care team involvement at PM or elsewhere; and (iv) Not receiving ongoing follow up with malignant hematology team at PM.

Caregiver eligibility criteria:

Inclusion criteria:

(i) Age ≥18 years; (ii) Caregiver of a patient with relapsed B cell lymphoma; and (iii) Willing to attend at least 1 PCC visit with the patient.

Exclusion criteria:

(i) Insufficient verbal and/or written English literacy to complete study procedures; or (ii) Patient not participating in study.

Healthcare provider eligibility criteria:

Inclusion criteria:

(i) Specialized staff physician, fellow, clinical nurse specialist, or clinic nurse from the outpatient malignant hematology team or palliative care team at PM working clinically with patients with multiple myeloma; and (ii) Working in their clinical area for at least 12 months.

Where it's running

• Princess Margaret Cancer Centre
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Breffni Hannon, MB BCh BAO, MMedSci, MCFP — Princess Margaret Cancer Centre
• Study coordinator: Breffni Hannon, MB BCh BAO, MMedSci, MCFP
• Email: Breffni.Hannon@uhn.ca
• Phone: 416-946-4501

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sequential CAR-T therapy targeting BCMA and GPRC5D for relapsed or refractory multiple myeloma

  This will try sequential CAR-T cell therapy against BCMA and GPRC5D in people with relapsed or refractory multiple myeloma to see if it is safe and helps control the disease.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07032129

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• Off-the-shelf BCMA CAR‑T for relapsed or refractory multiple myeloma

  This trial will try a universal (allogeneic) BCMA-directed CAR‑T cell treatment for people with relapsed or refractory multiple myeloma to see if it is safe and can reduce disease.

  Recruiting Bioray Laboratories · Shanghai · NCT07248176

• NT-I7 added to BCMA CAR-T therapy for relapsed or refractory multiple myeloma

  This trial tests whether giving NT-I7 after BCMA CAR-T therapy helps boost T-cell expansion and possibly improve responses in people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07200089

• In Vivo BCMA-CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

  This study tests VV169, a one-time in vivo CAR-T treatment, in adults with multiple myeloma that has come back or not responded to standard therapy.

  Recruiting Phase 1 Vyriad, Inc. · Rochester, Minnesota · NCT07802717

• Inobrodib with Pomalidomide and Dexamethasone vs Standard Therapy for Relapsed or Refractory Myeloma

  This study tests whether inobrodib with pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma more than the standard available therapy.

  Recruiting Phase 3 CellCentric Ltd. · Miami, Florida · NCT07772024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.